Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27283486,area-under the time-activity curve,Lop kinetics and radiometabolites in arterial plasma were measured to calculate [(11)C]dLop area-under the time-activity curve from 10 to 30min in the brain (AUCbrain) and in plasma (AUCplasma).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),min,10 to 30,5092,DB00975,Dipyridamole
,27283486,AUCR,Baseline AUCR (0.85±0.29) was significantly enhanced in the presence of CsA (AUCR=10.8±3.6).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,0.85,5093,DB00975,Dipyridamole
,27283486,AUCR,Baseline AUCR (0.85±0.29) was significantly enhanced in the presence of CsA (AUCR=10.8±3.6).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,10.8,5094,DB00975,Dipyridamole
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,1.2,5095,DB00975,Dipyridamole
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,0.9,5096,DB00975,Dipyridamole
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,1.1,5097,DB00975,Dipyridamole
,7054239,Tl-201 clearance,"The mean 4-h fractional myocardial Tl-201 clearance for nonstenotic zones was 0.35, 0.27 for group 2 stenotic zones, 0.19 for group 3 stenotic zones, and 0.05 for group 4 stenotic zones (P less than 0.0001).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),,0.35,14650,DB00975,Dipyridamole
,7054239,Tl-201 clearance,"The mean 4-h fractional myocardial Tl-201 clearance for nonstenotic zones was 0.35, 0.27 for group 2 stenotic zones, 0.19 for group 3 stenotic zones, and 0.05 for group 4 stenotic zones (P less than 0.0001).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),,0.27,14651,DB00975,Dipyridamole
,7054239,Tl-201 clearance,"The mean 4-h fractional myocardial Tl-201 clearance for nonstenotic zones was 0.35, 0.27 for group 2 stenotic zones, 0.19 for group 3 stenotic zones, and 0.05 for group 4 stenotic zones (P less than 0.0001).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),,0.19,14652,DB00975,Dipyridamole
,7054239,Tl-201 clearance,"The mean 4-h fractional myocardial Tl-201 clearance for nonstenotic zones was 0.35, 0.27 for group 2 stenotic zones, 0.19 for group 3 stenotic zones, and 0.05 for group 4 stenotic zones (P less than 0.0001).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),,0.05,14653,DB00975,Dipyridamole
,7054239,final decay constant lambda 2,"After reaching peak activity, myocardial Tl-201 activity cleared biexponentially with a final decay constant lambda 2 = 0.0017 +/- 0.0001 min-1 (SE) for nonstenotic zones, 0.0011 +/- 0.0001 min-1 for group 2 stenotic zones, and 0.0006 +/- 0.0001 min-1 for group 3 stenotic zones (P less than 0.01).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),1/[min],0.0017,14654,DB00975,Dipyridamole
,7054239,final decay constant lambda 2,"After reaching peak activity, myocardial Tl-201 activity cleared biexponentially with a final decay constant lambda 2 = 0.0017 +/- 0.0001 min-1 (SE) for nonstenotic zones, 0.0011 +/- 0.0001 min-1 for group 2 stenotic zones, and 0.0006 +/- 0.0001 min-1 for group 3 stenotic zones (P less than 0.01).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),1/[min],0.0011,14655,DB00975,Dipyridamole
,7054239,final decay constant lambda 2,"After reaching peak activity, myocardial Tl-201 activity cleared biexponentially with a final decay constant lambda 2 = 0.0017 +/- 0.0001 min-1 (SE) for nonstenotic zones, 0.0011 +/- 0.0001 min-1 for group 2 stenotic zones, and 0.0006 +/- 0.0001 min-1 for group 3 stenotic zones (P less than 0.01).",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),1/[min],0.0006,14656,DB00975,Dipyridamole
,7054239,blood lambda 3,"Blood Tl-201 activity decayed triexponentially with a final blood lambda 3 = 0.0018 +/- 0.0001 min-1, which was almost identical to the final myocardial lambda 2 decay constant.",Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7054239/),1/[min],0.0018,14657,DB00975,Dipyridamole
,19509274,maximum inhibition,"However, maximum inhibition of thymidine incorporation into tumors was only 50%, which was insufficient to enhance pemetrexed antitumor activity in vivo.",Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509274/),%,50,43494,DB00975,Dipyridamole
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.25,67452,DB00975,Dipyridamole
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.27,67453,DB00975,Dipyridamole
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.31,67454,DB00975,Dipyridamole
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.26,67455,DB00975,Dipyridamole
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.37,67456,DB00975,Dipyridamole
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,4.4,67457,DB00975,Dipyridamole
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,2.1,67458,DB00975,Dipyridamole
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,6.7,67459,DB00975,Dipyridamole
,12545143,50% inhibitory concentration,Dipyridamole inhibited [(3)H]digoxin transport in Caco-2 cells with a 50% inhibitory concentration value of 1.5 +/- 1.5 micromol/L.,Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545143/),[μM] / [l],1.5,73222,DB00975,Dipyridamole
,12545143,AUC from 0 to 4 hours,"Digoxin AUC from 0 to 4 hours and AUC from 0 to 24 hours were significantly higher among subjects harboring the TT compared with the CC MDR1 genotype: 7.5 +/- 1.2 ng x h x mL(-1) versus 6.1 +/- 0.8 ng x h x mL(-1) and 20.2 +/- 2.1 ng x h x mL(-1) versus 16.8 +/- 1.7 ng x h x mL(-1), respectively (P <.05).",Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545143/),[h·ng] / [ml],7.5,73223,DB00975,Dipyridamole
,12545143,AUC from 0 to 24 hours,"Digoxin AUC from 0 to 4 hours and AUC from 0 to 24 hours were significantly higher among subjects harboring the TT compared with the CC MDR1 genotype: 7.5 +/- 1.2 ng x h x mL(-1) versus 6.1 +/- 0.8 ng x h x mL(-1) and 20.2 +/- 2.1 ng x h x mL(-1) versus 16.8 +/- 1.7 ng x h x mL(-1), respectively (P <.05).",Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545143/),[h·ng] / [ml],20.2,73224,DB00975,Dipyridamole
,12545143,AUC from 0 to 24 hours,"Digoxin AUC from 0 to 4 hours and AUC from 0 to 24 hours were significantly higher among subjects harboring the TT compared with the CC MDR1 genotype: 7.5 +/- 1.2 ng x h x mL(-1) versus 6.1 +/- 0.8 ng x h x mL(-1) and 20.2 +/- 2.1 ng x h x mL(-1) versus 16.8 +/- 1.7 ng x h x mL(-1), respectively (P <.05).",Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545143/),[h·ng] / [ml],16.8,73225,DB00975,Dipyridamole
,7197020,urinary excretion,The urinary excretion of dipyridamole was 1.37 mg/day (0.6% of the daily dose) and was significantly lower between 18.00--2.00 hr in comparison with excretion between 2.00--0.00 and 10.00-18.00.,Does a rhythmicity of serum concentrations and urinary excretion of dipyridamole exist during long-term treatment? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197020/),[mg] / [d],1.37,99325,DB00975,Dipyridamole
,7197020,excretion,The urinary excretion of dipyridamole was 1.37 mg/day (0.6% of the daily dose) and was significantly lower between 18.00--2.00 hr in comparison with excretion between 2.00--0.00 and 10.00-18.00.,Does a rhythmicity of serum concentrations and urinary excretion of dipyridamole exist during long-term treatment? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197020/),,2.00--0.00,99326,DB00975,Dipyridamole
,7197020,excretion,The urinary excretion of dipyridamole was 1.37 mg/day (0.6% of the daily dose) and was significantly lower between 18.00--2.00 hr in comparison with excretion between 2.00--0.00 and 10.00-18.00.,Does a rhythmicity of serum concentrations and urinary excretion of dipyridamole exist during long-term treatment? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7197020/),,10.00-18.00,99327,DB00975,Dipyridamole
,24368104,relative bioavailability,"The pharmacokinetic study was conducted in beagle dogs, and the relative bioavailability of the test preparation was 193.11±3.43%.",A novel gastro-floating multiparticulate system for dipyridamole (DIP) based on a porous and low-density matrix core: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368104/),%,193.11,101140,DB00975,Dipyridamole
,8067734,free/total dipyridamole ratio,"Dipyridamole was highly protein bound, with a median free/total dipyridamole ratio of 0.7%; the percent free/total dipyridamole ratio was inversely correlated with alpha 1 acid glycoprotein concentrations (r2 =0.66).",Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067734/),%,0.7,114476,DB00975,Dipyridamole
,7218380,half-life (t1/2),2) The blood level of radioactivity after oral administration showed a monophasic slow elimination with a half-life (t1/2) of about 10 hrs.,Comparative studies on the fate of 14C-dipyridamole (RA8) after single and multiple administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7218380/),h,10,114835,DB00975,Dipyridamole
,7218380,t1/2,"The apparent absorption rate was not so high (t1/2 : 0.72 hr), therefore, it took about 3 hrs to reach the maximum level.",Comparative studies on the fate of 14C-dipyridamole (RA8) after single and multiple administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7218380/),h,0.72,114836,DB00975,Dipyridamole
,7218380,t1/2,"3) When the drug was applied intravenously, radioactivity in blood decreased tri-phasically, but the terminal phase, which appeared 12 hrs after the application, showed the same elimination rate as that of p. o. application, i.e., t1/2 : about 10 hrs.",Comparative studies on the fate of 14C-dipyridamole (RA8) after single and multiple administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7218380/),h,10,114837,DB00975,Dipyridamole
,7446135,half-lives,"The half-lives of the alpha-phase of distribution and of the beta-phase of disposition were about 1.4 and 6.3 min., respectively.",Myocardial pharmacokinetics and pharmacodynamics of dipyridamole in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446135/),min,1.4,119484,DB00975,Dipyridamole
,7446135,half-lives,"The half-lives of the alpha-phase of distribution and of the beta-phase of disposition were about 1.4 and 6.3 min., respectively.",Myocardial pharmacokinetics and pharmacodynamics of dipyridamole in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446135/),min,6.3,119485,DB00975,Dipyridamole
,7959316,clearance index,The clearance index of d4T was 0.24 +/- 0.07 at 1.0 micrograms/ml and 0.235 +/- 0.045 at 10.0 micrograms/ml.,The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959316/),,0.24,122016,DB00975,Dipyridamole
,7959316,clearance index,The clearance index of d4T was 0.24 +/- 0.07 at 1.0 micrograms/ml and 0.235 +/- 0.045 at 10.0 micrograms/ml.,The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959316/),,0.235,122017,DB00975,Dipyridamole
,9449537,terminal half-life,"Zalcitabine plasma concentrations declined rapidly in a bi-exponential fashion, with a terminal half-life of 1.03 +/- 0.18 hr. alone versus 1.08 +/- 0.22 hr. with dipyridamole.",Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449537/),h,1.03,122643,DB00975,Dipyridamole
,9449537,terminal half-life,"Zalcitabine plasma concentrations declined rapidly in a bi-exponential fashion, with a terminal half-life of 1.03 +/- 0.18 hr. alone versus 1.08 +/- 0.22 hr. with dipyridamole.",Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449537/),h,1.08,122644,DB00975,Dipyridamole
,9449537,ClR,"ClR, was 1.42 +/- 0.37 l/hr./kg for zalcitabine alone versus 1.09 +/- 0.28 l/hr./kg with dipyridamole.",Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449537/),[l] / [·h·kg],1.42,122645,DB00975,Dipyridamole
,9449537,ClR,"ClR, was 1.42 +/- 0.37 l/hr./kg for zalcitabine alone versus 1.09 +/- 0.28 l/hr./kg with dipyridamole.",Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449537/),[l] / [·h·kg],1.09,122646,DB00975,Dipyridamole
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.9,122908,DB00975,Dipyridamole
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.1,122909,DB00975,Dipyridamole
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.2,122910,DB00975,Dipyridamole
,6579711,terminal half-life,Concentrations after the intravenous dose showed a tri-exponential decline with a terminal half-life of 11.6 +/- 2.2 hr (mean +/- S.D.).,Clinical pharmacokinetics of dipyridamole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6579711/),h,11.6,123297,DB00975,Dipyridamole
,6579711,Total plasma clearance,Total plasma clearance was 138 +/- 30 ml/min and the apparent volume of distribution was 141 +/- 51 l.,Clinical pharmacokinetics of dipyridamole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6579711/),[ml] / [min],138,123298,DB00975,Dipyridamole
,6579711,apparent volume of distribution,Total plasma clearance was 138 +/- 30 ml/min and the apparent volume of distribution was 141 +/- 51 l.,Clinical pharmacokinetics of dipyridamole. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6579711/),l,141,123299,DB00975,Dipyridamole
,6579711,Systemic availability,Systemic availability of the oral dose was 52 +/- 23%.,Clinical pharmacokinetics of dipyridamole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6579711/),%,52,123300,DB00975,Dipyridamole
,6579711,Plasma protein binding,Plasma protein binding was 99.13 +/- 0.24%.,Clinical pharmacokinetics of dipyridamole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6579711/),%,99.13,123301,DB00975,Dipyridamole
,2328492,steady-state FUra plasma concentration,"At the maximal tolerated dose of FUra, 2300 mg/m2/day x3, mean steady-state FUra plasma concentration and total body clearance were 6.6 microM and 122 liters/h/m2, respectively, for courses of the combination.",Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328492/),μM,6.6,125730,DB00975,Dipyridamole
,2328492,total body clearance,"At the maximal tolerated dose of FUra, 2300 mg/m2/day x3, mean steady-state FUra plasma concentration and total body clearance were 6.6 microM and 122 liters/h/m2, respectively, for courses of the combination.",Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328492/),[l] / [h·m2],122,125731,DB00975,Dipyridamole
,3733279,tmax,"The tmax for the preparations, expressed as mean +/- s mean amounts as follows: A: 0.8 +/- 0.06; B: 1.1 +/- 0.1; C: 0.8 +/- 0.09 hours and is in the case of B significantly different (p less than 0.05) from the others.",The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),h,0.8,125897,DB00975,Dipyridamole
,3733279,tmax,"The tmax for the preparations, expressed as mean +/- s mean amounts as follows: A: 0.8 +/- 0.06; B: 1.1 +/- 0.1; C: 0.8 +/- 0.09 hours and is in the case of B significantly different (p less than 0.05) from the others.",The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),h,1.1,125898,DB00975,Dipyridamole
,3733279,tmax,"The tmax for the preparations, expressed as mean +/- s mean amounts as follows: A: 0.8 +/- 0.06; B: 1.1 +/- 0.1; C: 0.8 +/- 0.09 hours and is in the case of B significantly different (p less than 0.05) from the others.",The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),h,0.8,125899,DB00975,Dipyridamole
,3733279,cmax,The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different.,The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),[μM] / [l],1.01,125900,DB00975,Dipyridamole
,3733279,cmax,The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different.,The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),[μM] / [l],1.16,125901,DB00975,Dipyridamole
,3733279,cmax,The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different.,The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),[μM] / [l],1.51,125902,DB00975,Dipyridamole
,3733279,AUC,The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different.,The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),[h·μM] / [l],3.8,125903,DB00975,Dipyridamole
,3733279,AUC,The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different.,The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),[h·μM] / [l],3.1,125904,DB00975,Dipyridamole
,3733279,AUC,The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different.,The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3733279/),[h·μM] / [l],3.8,125905,DB00975,Dipyridamole
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],8.5,131399,DB00975,Dipyridamole
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],1.3,131400,DB00975,Dipyridamole
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],1,132975,DB00975,Dipyridamole
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],15,132976,DB00975,Dipyridamole
,15951475,relative bioavailability,DP relative bioavailability was reduced 53% with conventional tablets compared to the composite buffered ER capsule in reduced gastric acid conditions.,Dipyridamole bioavailability in subjects with reduced gastric acidity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951475/),%,53,136569,DB00975,Dipyridamole
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],398,143694,DB00975,Dipyridamole
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],301,143695,DB00975,Dipyridamole
,8971428,AUCEPO,"The AUCEPO (0,72 h) were not statistically significantly different (theophylline: 398 +/- 30, dipyridamole: 301 +/- 15, placebo: 332 +/- 57 [mu ml-1 h]).",Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971428/),[h·mu] / [ml],332,143696,DB00975,Dipyridamole
,2825745,terminal half life,"The concentrations declined in a biexponential fashion, with a terminal half life of 24.1 +/- 1.9 h (mean +/- s.e. mean).",Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2825745/),h,24.1,152727,DB00975,Dipyridamole
,1570231,area under the dipyridamole concentration-time curve from 0-4 hours,The area under the dipyridamole concentration-time curve from 0-4 hours ranged from 2.9-2.3 microgram.hr/ml.,Disposition of oral dipyridamole in patients undergoing thallium 201 myocardial imaging. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570231/),[h·μg] / [ml],2.9-2.3,154072,DB00975,Dipyridamole
,1570231,time to peak plasma level,"The time to peak plasma level for dipyridamole ranged from 0.5-2.5 hours, with two patients having undetectable levels at the time of thallium 201 injection.",Disposition of oral dipyridamole in patients undergoing thallium 201 myocardial imaging. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570231/),h,0.5-2.5,154073,DB00975,Dipyridamole
,22001837,C(max),"The C(max), T(max) and AUC((0→24)) of CAP(1) were 0.78 ± 0.23 (μg/ml), 3.80 ± 0.30 (h), and 6.74 ± 0.47 (μg/mlh), respectively.",Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001837/),,0.78,163650,DB00975,Dipyridamole
,22001837,T(max),"The C(max), T(max) and AUC((0→24)) of CAP(1) were 0.78 ± 0.23 (μg/ml), 3.80 ± 0.30 (h), and 6.74 ± 0.47 (μg/mlh), respectively.",Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001837/),h,3.80,163651,DB00975,Dipyridamole
,22001837,AUC((0→24)),"The C(max), T(max) and AUC((0→24)) of CAP(1) were 0.78 ± 0.23 (μg/ml), 3.80 ± 0.30 (h), and 6.74 ± 0.47 (μg/mlh), respectively.",Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001837/),[μg] / [mlh],6.74,163652,DB00975,Dipyridamole
,22001837,relative bioavailability,The relative bioavailability of CAP(1) was 71.55% compared with IRT.,Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001837/),%,71.55,163653,DB00975,Dipyridamole
,1643698,steady-state FUra concentrations,Limited pharmacokinetic sampling at levels 3 and 4 revealed mean steady-state FUra concentrations of around 1.0 microM with infusions of FUra/LV+DP.,"A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643698/),μM,1.0,167173,DB00975,Dipyridamole
,474151,disposition rate constants (beta),The disposition rate constants (beta) were within the range of 0.0051--0.0083 min.-1 corresponding to biological half-lives of 84--145 min.,Pharmacokinetics of dipyridamole. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474151/),-1·min,0.0051--0.0083,181034,DB00975,Dipyridamole
,474151,biological half-lives,The disposition rate constants (beta) were within the range of 0.0051--0.0083 min.-1 corresponding to biological half-lives of 84--145 min.,Pharmacokinetics of dipyridamole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474151/),min,84,181035,DB00975,Dipyridamole
,474151,absorption rate constant,"The absorption rate constant was about 0.07 min.-1, and the systemic availability of an oral dose of 100 mg dipyridamole in tablets varied from 37 to 66%.",Pharmacokinetics of dipyridamole. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474151/),-1·min,0.07,181036,DB00975,Dipyridamole
,474151,systemic availability,"The absorption rate constant was about 0.07 min.-1, and the systemic availability of an oral dose of 100 mg dipyridamole in tablets varied from 37 to 66%.",Pharmacokinetics of dipyridamole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/474151/),%,37 to 66,181037,DB00975,Dipyridamole
less,6628545,half-life,"The half-life for adenosine in undiluted blood was less than 10 s; therefore, to accurately evaluate the effects of dipyridamole, blood was diluted 1 : 12 in isotonic saline.",Dipyridamole inhibition of adenosine metabolism in human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628545/),s,10,185362,DB00975,Dipyridamole
,6628545,half-life,"At this dilution, the half-life for adenosine was 1.3 min.",Dipyridamole inhibition of adenosine metabolism in human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628545/),min,1.3,185363,DB00975,Dipyridamole
,1733557,t1/2,"DP significantly increased the mean t1/2 for [3H]-ara-CTP from 102 to 136 min (P less than 0.01), but this effect was much less pronounced than that obtained for total tritium and the increase was quite variable (0-70%; median, 19%).",Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733557/),min,102 to 136,186537,DB00975,Dipyridamole
,7738622,objective response rate,An objective response rate of 15% (one complete response [CR] and 13 partial responses [PRs]) for 5-FU/FA and 13% (two CRs and nine PRs) for 5-FU/FA/DP was observed.,Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),%,15,207980,DB00975,Dipyridamole
,7738622,objective response rate,An objective response rate of 15% (one complete response [CR] and 13 partial responses [PRs]) for 5-FU/FA and 13% (two CRs and nine PRs) for 5-FU/FA/DP was observed.,Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),%,13,207981,DB00975,Dipyridamole
,7738622,time to progression,"The median time to progression (P = .8) and the median survival time (11.6 months for 5-FU/FA v 9.3 months for 5-FU/FA/DP; P = .14, log-rank test) were not different between treatment arms.",Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),month,11.6,207982,DB00975,Dipyridamole
,7738622,survival time,"The median time to progression (P = .8) and the median survival time (11.6 months for 5-FU/FA v 9.3 months for 5-FU/FA/DP; P = .14, log-rank test) were not different between treatment arms.",Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738622/),month,9.3,207983,DB00975,Dipyridamole
,2023280,maximum tolerated,The maximum tolerated dose of etoposide was 175 mg/m2 per day when administered with dipyridamole at a fixed dose of 24 mg/m2 per day.,Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023280/),,175,220996,DB00975,Dipyridamole
,32116078,intrinsic clearances (CLint),"The intrinsic clearances (CLint) values of M1 and M4 in HLM were 48.10 and 184.03 μL/min/mg, respectively.","Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116078/),[μl] / [mg·min],48.10,234893,DB00975,Dipyridamole
,32116078,intrinsic clearances (CLint),"The intrinsic clearances (CLint) values of M1 and M4 in HLM were 48.10 and 184.03 μL/min/mg, respectively.","Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116078/),[μl] / [mg·min],184.03,234894,DB00975,Dipyridamole
,32116078,CLint,"Additionally, CYP1A1, 2C8 and 2C19 were identified as main contributors with CLint values of 13.01-49.36 μL/min/mg, while UGT1A1, 1A7, 1A8 and 1A9 were with CLint values ranging from 85.01 to 284.07 μL/min/mg.","Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116078/),[μl] / [mg·min],13.01-49.36,234895,DB00975,Dipyridamole
,32116078,CLint,"Additionally, CYP1A1, 2C8 and 2C19 were identified as main contributors with CLint values of 13.01-49.36 μL/min/mg, while UGT1A1, 1A7, 1A8 and 1A9 were with CLint values ranging from 85.01 to 284.07 μL/min/mg.","Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116078/),[μl] / [mg·min],85.01 to 284.07,234896,DB00975,Dipyridamole
,2532072,response rate,"This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients.",Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532072/),%,15,240812,DB00975,Dipyridamole
,11124230,apparent K(m),"The uptake of YH1885 into the Caco-2 cell monolayer was saturable and appeared to be mediated by a high-affinity transporter, with an apparent K(m) of 1.47+/-0.21 microM and a V(max) of 25.14+/-1.16 pmol/cm(2)/40 s.","The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124230/),μM,1.47,243221,DB00975,Dipyridamole
,11124230,V(max),"The uptake of YH1885 into the Caco-2 cell monolayer was saturable and appeared to be mediated by a high-affinity transporter, with an apparent K(m) of 1.47+/-0.21 microM and a V(max) of 25.14+/-1.16 pmol/cm(2)/40 s.","The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124230/),[pM] / [40·cm(2)·s],25.14,243222,DB00975,Dipyridamole
,11124230,solubility,"Saturation of this transport system, in addition to the limited solubility of YH1885 (i.e., approximately 5.3 microM), appears to contribute to the dose-dependent bioavailability of the drug.","The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124230/),μM,5.3,243223,DB00975,Dipyridamole
,11127945,clearance,"The median clearance of VP-16 was 0.96 l/h per m2 (range 0.8-1.5 l/h per m2), which is lower than for VP-16 alone and similar to previously reported effects of CSA on VP-16 elimination.","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),[l] / [h·m2],0.96,245132,DB00975,Dipyridamole
,11127945,AUC,The median measured CBDCA AUC was 3.0 mg/ml x min (range 2.4-4.8 mg/ml x min).,"A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),[mg] / [min·ml],3.0,245133,DB00975,Dipyridamole
,11127945,plasma concentrations,"The median end of infusion PCZ and total DP plasma concentrations were 1.2 microM (range 0.5-2.2 microM) and 4.4 microM (range 1.3-5.9 microM), respectively, consistent with in vitro resistance modulatory levels.","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),μM,4.4,245134,DB00975,Dipyridamole
,11127945,free,"However, free DP was only 0.02 microM (range 0.004-0.04 microM).","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),μM,0.02,245135,DB00975,Dipyridamole
,3433258,concentrations of,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],26,247723,DB00975,Dipyridamole
,3433258,concentrations of,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],79,247724,DB00975,Dipyridamole
,3433258,at steady-state,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],26,247725,DB00975,Dipyridamole
,3433258,at steady-state,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],79,247726,DB00975,Dipyridamole
,3433258,steady-state concentrations,"The average steady-state concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day.",Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[μg] / [ml],0.67,247727,DB00975,Dipyridamole
,3433258,steady-state concentrations,"The average steady-state concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day.",Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[μg] / [ml],3.76,247728,DB00975,Dipyridamole
,3334996,peritoneal half-life,"The mean peritoneal half-life for total extractable dipyridamole was 3.3 +/- 1.9 (SD) h, and the mean peritoneal clearance was 0.4 +/- 0.3 liters/h/m2.",Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),h,3.3,249248,DB00975,Dipyridamole
,3334996,peritoneal clearance,"The mean peritoneal half-life for total extractable dipyridamole was 3.3 +/- 1.9 (SD) h, and the mean peritoneal clearance was 0.4 +/- 0.3 liters/h/m2.",Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),[l] / [h·m2],0.4,249249,DB00975,Dipyridamole
,3334996,plasma half-life,"The mean plasma half-life of total dipyridamole in our patients was 2.2 +/- 1.2 h, and the mean clearance value was 5.7 +/- 4.7 liters/h/m2.",Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),h,2.2,249250,DB00975,Dipyridamole
,3334996,clearance,"The mean plasma half-life of total dipyridamole in our patients was 2.2 +/- 1.2 h, and the mean clearance value was 5.7 +/- 4.7 liters/h/m2.",Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),[l] / [h·m2],5.7,249251,DB00975,Dipyridamole
,3334996,area under the concentration versus time curve,The area under the concentration versus time curve was calculated to be 626 +/- 312 microM-h for the peritoneal cavity and 45 +/- 20 microM-h for the plasma.,Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),μM-h,626,249252,DB00975,Dipyridamole
,3334996,area under the concentration versus time curve,The area under the concentration versus time curve was calculated to be 626 +/- 312 microM-h for the peritoneal cavity and 45 +/- 20 microM-h for the plasma.,Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),μM-h,45,249253,DB00975,Dipyridamole
,3334996,plasma clearance,"While the peritoneal clearance values of free and total drug are comparable, the plasma clearance of free dipyridamole was 47 +/- 39 liters/h/m2.",Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),[l] / [h·m2],47,249254,DB00975,Dipyridamole
,3334996,plasma area under the concentration versus time curve,"This increased plasma clearance resulted in a plasma area under the concentration versus time curve of 8.3 +/- 5.1 microM-h, which suggests minimal systemic exposure.",Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3334996/),μM-h,8.3,249255,DB00975,Dipyridamole
,2362197,first-pass retention fraction,Myocardial first-pass retention fraction averaged 0.90 +/- 0.04.,Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362197/),,0.90,259100,DB00975,Dipyridamole
,2362197,half-time,"Sixty-seven percent of retained activity cleared with a half-time of 2.3 +/- 0.6 min, while the residual activity demonstrated slow clearance.",Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362197/),min,2.3,259101,DB00975,Dipyridamole
,2362197,clearance rate,Myocardial SQ30217 clearance rate following i.v. injection as determined by dynamic imaging with tomography (SPRINT) averaged 21 +/- 4 min and increased to 13 +/- 4 min following dipyridamole.,Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362197/),min,21,259102,DB00975,Dipyridamole
,2362197,clearance rate,Myocardial SQ30217 clearance rate following i.v. injection as determined by dynamic imaging with tomography (SPRINT) averaged 21 +/- 4 min and increased to 13 +/- 4 min following dipyridamole.,Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362197/),min,13,259103,DB00975,Dipyridamole
,19630071,flow rate,"After protein precipitation of 200 microL plasma with methanol, dipyridamole and diazepam (internal standard) were chromatographed on an Ultimate XB-C(18) (50 x 2.1 mm i.d, 3 microm) column with the mobile phase consisting of methanol-ammonium acetate (5 mM; 80 : 20, v/v) at a flow rate of 0.25 mL/min.",Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630071/),[ml] / [min],0.25,269725,DB00975,Dipyridamole
,19630071,retention times,"The retention times of dipyridamole and diazepam were 1.4 and 1.2 min, respectively.",Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630071/),min,1.4,269726,DB00975,Dipyridamole
,19630071,retention times,"The retention times of dipyridamole and diazepam were 1.4 and 1.2 min, respectively.",Quantitative determination of dipyridamole in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19630071/),min,1.2,269727,DB00975,Dipyridamole
